Ovarian Cancer Diagnostics Market Size to Reach USD 8.08 Billion by 2035 | SNS Insider

The global ovarian cancer diagnostics market is valued at USD 4.92 billion in 2025 and is projected to reach USD 8.08 billion by 2035, growing at a CAGR of 5.06%. Growth is driven by rising ovarian cancer incidence, increasing adoption of AI-powered imaging, biomarker testing, and precision oncology diagnostics. North America leads with 41.2% market share, while imaging and hospital laboratories dominate their respective segments.

06/19/2026, 5:39 AM • GlobeNewswire

Over 100 Organizations Thank America’s Blood Donors on World Blood Donor Day

More than 100 prominent organizations have united to promote World Blood Donor Day on June 14, 2026, and Blood Advocacy Week (June 8-12). The initiative highlights that while blood transfusions are needed every 2 seconds in America, less than 3% of eligible Americans donate blood. The campaign theme is 'One Drop of Humanity. Give Blood. Save Lives.' emphasizing the critical need for volunteer blood donors.

06/14/2026, 8:54 AM • GlobeNewswire

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

GSK announced a $10.6 billion all-cash acquisition of Nuvalent at $124 per share, representing a 40% premium. The deal reflects Big Pharma's aggressive capital deployment to address an impending patent cliff, as GSK faces revenue loss from dolutegravir's expiring exclusivity. Nuvalent brings two late-stage kinase inhibitors targeting non-small cell lung cancer with FDA Breakthrough Therapy designations, triggering a short squeeze and signaling potential industry consolidation in oncology.

06/11/2026, 1:18 PM • Investing

Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery

Nxera Pharma has joined OpenFold, a non-profit AI research consortium for drug discovery, alongside major pharmaceutical and technology companies including Bristol Myers Squibb, Novo Nordisk, Bayer, Roche, AWS, Microsoft, and NVIDIA. The participation aligns with Nxera's strategy to enhance R&D productivity through AI technologies and leverage its NxWave™ GPCR drug discovery platform with open-source structural prediction models.

06/10/2026, 2:35 AM • GlobeNewswire

Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market

Nurix Therapeutics announced a strategic partnership with Roche to co-develop and co-commercialize bexobrutideg, a BTK degrader for B-cell blood cancers. Nurix will receive $700 million upfront with potential milestone payments up to $2.3 billion total. The companies will share development costs (40/60 split) and equally split U.S. commercialization profits, while Roche handles international sales with royalties to Nurix. NRIX stock surged 51.23% in premarket trading.

06/08/2026, 9:26 AM • Benzinga

New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people living with overweight and obesity

Zealand Pharma announced Phase 2 ZUPREME-1 trial results showing petrelintide, an amylin analog, achieved clinically meaningful double-digit weight loss (up to 10.7% vs 1.7% placebo) with placebo-like tolerability and low GI adverse event discontinuation rates (1.5%). The treatment also improved cardiometabolic risk factors. Phase 3 trials are planned for the second half of 2026.

06/05/2026, 4:45 PM • GlobeNewswire

Chemiluminescence Immunoassay Market Expected to Reach USD 16.39 Billion by 2031 | MarketsandMarkets™

The global chemiluminescence immunoassay (CLIA) market is projected to grow from USD 11.58 billion in 2026 to USD 16.39 billion by 2031, with a CAGR of 7.2%. Growth is driven by rising demand for high-sensitivity diagnostic testing, automated laboratory systems, increasing prevalence of chronic and infectious diseases, and technological advancements including AI-enabled automation. Asia Pacific is emerging as a high-growth region, while hospitals lead market adoption.

06/05/2026, 10:30 AM • GlobeNewswire

[Latest] Non-Invasive Blood Glucose Monitoring Devices Market Size to Hit USD 340.49 Million with a Promising CAGR of 25.60% by 2034 - Report by Zion Market Research (ZMR)

The global non-invasive blood glucose monitoring devices market is projected to grow from USD 34.86 million in 2024 to USD 340.49 million by 2034, with a CAGR of 25.60%. Growth is driven by rising diabetes prevalence, increasing demand for painless monitoring, and technological advancements in wearables and optical sensing. Spectroscopy technology and homecare segments are expected to lead the market, while North America will dominate regionally.

06/04/2026, 1:53 PM • GlobeNewswire

Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection

Roche announced it developed a Research Use Only (RUO) molecular PCR test via subsidiary TIB MOLBIOL within six days to detect the rare Ebola Bundibugyo virus. The test supports outbreak response efforts in Central and East Africa following WHO's declaration of a Public Health Emergency of International Concern on May 17, 2026. Roche is working with public health laboratories and authorities in affected regions to deploy the testing capability.

06/04/2026, 11:33 AM • Benzinga

IEFA: Why This Fund Is One of the Best International ETFs

The iShares Core MSCI EAFE ETF (IEFA) is highlighted as one of the best international ETFs, offering diversified exposure to over 2,600 stocks across 16+ developed markets with a low 0.07% expense ratio and 3.30% dividend yield. While it has underperformed the S&P 500 recently, the fund provides valuable portfolio diversification and could serve as a hedge against U.S. market volatility, particularly if tech stocks decline from current valuations.

06/04/2026, 10:30 AM • The Motley Fool

Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?

Recursion Pharmaceuticals and Schrödinger represent different approaches to AI-driven drug discovery—one biotech-focused with clinical-stage programs, the other software-first with recurring revenue. While both show strong growth (26.9% and 23.3% respectively), Recursion trades at a premium valuation (26.1x P/S) with significant losses and no approved products, while Schrödinger has a lower P/S ratio (4.3x) and improving profitability. The analyst recommends neither stock currently but would choose Schrödinger if forced to pick, citing its established software business and improving financial trajectory.

06/02/2026, 5:12 PM • The Motley Fool

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting

The FDA has accepted Roche's New Drug Application for giredestrant, an oral selective estrogen receptor degrader (SERD), for treating ER-positive, HER2-negative early-stage breast cancer under priority review. Phase III lidERA trial data showed giredestrant reduced the risk of invasive disease recurrence or death by 30% compared to standard-of-care endocrine therapy, representing the first major advance in adjuvant endocrine therapy in over 20 years. An FDA decision is expected by November 30, 2026.

06/02/2026, 1:00 AM • GlobeNewswire

President Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too?

President Trump's Q1 2026 financial disclosures revealed significant purchases of Eli Lilly stock, a major player in the booming anti-obesity drug market. The article cautions investors against simply copying political trades, emphasizing that investment decisions should be based on business fundamentals rather than celebrity or political endorsements. Eli Lilly's obesity treatments Mounjaro and Zepbound generated over $30 billion in combined sales in 2025, with analysts projecting the global anti-obesity drug market could exceed $95-200 billion. While Lilly maintains a strong competitive position with manufacturing advantages and a robust pipeline, its premium valuation already reflects years of future growth, presenting significant downside risk if sales slow or competition intensifies.

05/27/2026, 2:02 PM • The Motley Fool

Glioblastoma Multiforme Market Poised for Significant Growth at a CAGR of 13.2% During the Forecast Period (2026–2036), as Next-Generation Therapies Enter Late-Stage Development | DelveInsight

The glioblastoma multiforme market is expected to grow at a CAGR of 13.2% from 2026-2036, driven by next-generation therapies entering late-stage development. The market was valued at USD 900 million in 2025 across the 7MM, with approximately 38,000 incident cases. Key players including Avita Biomedical, Kazia Therapeutics, Laminar Pharma, and others are advancing innovative immunotherapies, targeted treatments, and personalized medicine approaches to address the poor prognosis of this aggressive brain tumor.

05/27/2026, 1:00 PM • GlobeNewswire

Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management

Roche announced the launch of its Liver Disease Panel, a comprehensive suite of certified algorithms designed to support chronic liver disease management. The panel includes LiverPRO, a CE-marked algorithm developed by Evido that requires only age and routine blood markers to detect liver fibrosis. The solution addresses the global health challenge of CLD affecting 1.5 billion people by enabling earlier detection and intervention across the patient care pathway.

05/27/2026, 1:00 AM • GlobeNewswire